Abstract:COVID-19 can cause irreversible lung damage from acute respiratory distress syndrome (ARDS), chronic respiratory failure associated with post COVID-19 de novo fibrosis or worsening of an underlying fibrotic lung disease. Pregnant women are at increased risk for invasive mechanical ventilation, extracorporeal membrane oxygenation, and death. The Centers for Disease Control and Prevention reported more than 22,000 hospitalizations and 161 deaths for COVID-19 in pregnant women. Between August 2020 and September 2… Show more
“…Eleven patients were transplanted in Korea, 10 of whom were alive after a median follow-up of 322 days [ 5 ]. Five patients, including two pregnant women, were transplanted in Detroit (USA), four of whom were alive after a median follow-up of 273 days [ 6 ]. Of particular interest is the report of the Austrian experience: 39,485 patients were hospitalized for COVID-19 in Austria between 1 January 2020, and 30 May 2021, of whom 2323 required mechanical ventilation and 183 received extra-corporeal membrane oxygenation (ECMO) support.…”
The management of lung transplant patients has continued to evolve in recent years. The year 2021 was marked by the publication of the International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation. There have been major changes in lung transplant programs over the last few years. This review will summarize the knowledge in anesthesia management of lung transplantation with the most recent data. It will highlight the following aspects which concern anesthesiologists more specifically: (1) impact of COVID-19, (2) future of transplantation for cystic fibrosis patients, (3) hemostasis management, (4) extracorporeal membrane oxygenation management, (5) early prediction of primary graft dysfunction, and (6) pain management.
“…Eleven patients were transplanted in Korea, 10 of whom were alive after a median follow-up of 322 days [ 5 ]. Five patients, including two pregnant women, were transplanted in Detroit (USA), four of whom were alive after a median follow-up of 273 days [ 6 ]. Of particular interest is the report of the Austrian experience: 39,485 patients were hospitalized for COVID-19 in Austria between 1 January 2020, and 30 May 2021, of whom 2323 required mechanical ventilation and 183 received extra-corporeal membrane oxygenation (ECMO) support.…”
The management of lung transplant patients has continued to evolve in recent years. The year 2021 was marked by the publication of the International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation. There have been major changes in lung transplant programs over the last few years. This review will summarize the knowledge in anesthesia management of lung transplantation with the most recent data. It will highlight the following aspects which concern anesthesiologists more specifically: (1) impact of COVID-19, (2) future of transplantation for cystic fibrosis patients, (3) hemostasis management, (4) extracorporeal membrane oxygenation management, (5) early prediction of primary graft dysfunction, and (6) pain management.
“…Additionally, the study design relied on information from medical documentation and/or discharge summaries from acute care hospitals and one long‐term acute care hospital that were not written in a uniform manner. Further, the total number of medical complications in acute care reported in Table 1 is likely an underrepresentation of the number of complications and more detailed explanations of specific complications experienced by patients who underwent BOLT due to COVID‐19 lung disease have been reported 1,15 . Discharge functional data for patients who transferred to acute care and did not return to IRF were not available for analysis; therefore, direct admission and discharge functional comparisons could be performed only for those patients who completed IPR.…”
Section: Discussionmentioning
confidence: 99%
“…The combination of these elements suggests that the severity of patients' functional impairments, educational needs, and need for psychosocial support is greater for those who underwent BOLT due to COVID-19 lung disease. 3,4,10,15 There remains a relative gap in our knowledge of the course of this novel group of patients admitted to IPR and there are only published case reports of patients with COVID-19 related pulmonary disease who underwent IPR following lung transplant. 15,17 The objective in reporting this retrospective review is to describe the IPR course of this patient population, identify common and potential medical complications in the postoperative period that affect functional progress, and present the outcomes of comprehensive, coordinated, interdisciplinary rehabilitation care for the management of these noteworthy patients.…”
Section: Introductionmentioning
confidence: 99%
“…Inpatient rehabilitation (IPR) provides individualized and collaborative care in the postacute care phase and has been shown to improve the functional status of posttransplant patients as well as managing their complex medical needs 8–10 . Reports have also been published describing successful IPR for patients recovering from COVID‐19, but there are limited data on the rehabilitation outcomes for patients who underwent bilateral orthotopic lung transplant (BOLT) secondary to COVID‐19 related end‐stage pulmonary disease 11–15 …”
Section: Introductionmentioning
confidence: 99%
“…Further, the procedure for bilateral lung transplant requires a greater level of postacute care medical monitoring, including larger surgical incisions that are at risk of complications, increased need for pain management and medication titrations, and greater activity restrictions. The combination of these elements suggests that the severity of patients' functional impairments, educational needs, and need for psychosocial support is greater for those who underwent BOLT due to COVID‐19 lung disease 3,4,10,15 …”
BackgroundCoronavirus disease (COVID‐19) has introduced a new subset of patients with acute end‐stage lung damage for which lung transplantation has been successfully performed.ObjectiveTo describe the inpatient rehabilitation course of patients who underwent bilateral lung transplant due to severe COVID‐19 pulmonary disease.DesignRetrospective chart review.SettingFree‐standing, academic, urban inpatient rehabilitation hospital.ParticipantsSeventeen patients aged 28–67 years old (mean 53.9 ± 10.7) who developed COVID‐19 respiratory failure and underwent bilateral lung transplant.InterventionsPatients participated in a comprehensive inpatient rehabilitation program including physical, occupational, and speech therapy tailored to the unique functional needs of each individual.Main Outcome MeasuresPrimary outcome measures of functional improvements, include mobility and self‐care scores on section GG of the Functional Abilities and Goals of the Improving Post‐Acute Care Transformation Act, as defined as quality measures by the Centers for Medicare and Medicaid Services. Other functional measures included 6 minute walk test, Berg balance scale, Mann Assessment of Swallowing Ability (MASA), and Cognition and Memory Functional Independence Measure (FIM) scores. Wilcoxon signed rank sum test was used to evaluate statistical significance of change between admission and discharge scores.ResultsFourteen patients completed inpatient rehabilitation. Self‐care (GG0130) mean score improved from 20.9 to 36.1. Mobility (GG0170) mean score improved from 30.7 to 70.7. Mean 6‐minute walk distance improved from 174.1 to 467.6 feet. Mean Berg balance scores improved from 18.6/56 to 36.3/56. MASA scores improved from 171.3 to 182.3. All functional measures demonstrated statistically significant improvements with p value ≤ .008, except for cognition and memory FIM scores, which did not show a statistically significant difference. A majority (76%) of patients discharged home.ConclusionThis new and unique patient population can successfully participate in a comprehensive inpatient rehabilitation program and achieve functional improvements despite medical complications.
Проблема формирования необратимых остаточных изменений после перенесенного вирусного повреждения легких при COVID-19 (COronaVIrus Disease 2019, новая коронавирусная инфекция) по прошествии двух лет пандемии остается важной и обсуждаемой. Это связано с большим числом пациентов, перенесших коронавирусную инфекцию (в т.ч. со значимым объемом поражения легких) и возможным неблагоприятным прогнозом с уменьшением качества и продолжительности жизни. С учетом того, что в последнее время активно применяется антифибротическая терапия ряда интерстициальных заболеваний легких (при идиопатическом легочном фиброзе и системных заболеваниях), рассматривается вопрос о возможном использовании этих средств и при неблагоприятном исходе COVID-19. Однако до сих пор точно неизвестно, насколько часто развивается фиброз в исходе новой коронавирусной инфекции, а также четко не выделены группы пациентов, которые могут иметь неблагоприятный прогноз в виде исхода в фиброз. В обзоре рассмотрены патогенетические аспекты возможного развития необратимых изменений у пациентов с COVID-19, предрасполагающие факторы, а также особенности диагностики с акцентом на КТ-визуализацию с собственными наблюдениями авторов.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.